Klotho Neurosciences, Inc. (KLTO) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Omaha, NE, 美国. 現任CEO為 Joseph A. Sinkule.
KLTO 擁有 IPO日期為 2022-04-29, 3 名全職員工, 在 NASDAQ Global Market, 市值為 $20.08M.
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.
